Keywords: Portugal, Medicines access, IHS Global Insight, Pfizer, Vyndaqel, Retail pharmacy savings, Orphan disease
Portuguese hospitals block access to new medicines as retail drug sector expected to meet savings goal
Article | 30 September 2011
Access to expensive medicines is becoming increasingly difficult in Portuguese public hospitals, while savings with retail pharmacy expenditure are expected ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
